Identifying diagnosis delays and treatment gaps in PsA: expert commentary
People with psoriatic arthritis (PsA) experience longer waits for diagnosis and receive less intensive treatment than those with rheumatoid arthritis,...
delays
FDA Delays Approval of Replimune’s Melanoma Therapy Despite Promising Trial Results
For now, the FDA has denied approval today of a new melanoma treatment developed by Replimune. The company’s lead drug...
Diagnostic delays and reduced DMARD therapy identified in psoriatic arthritis
Individuals with psoriatic arthritis (PsA) experience significantly longer delays to diagnosis and are less likely to receive early disease-modifying antirheumatic...
